(Q36832121)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Current role of antibody therapy in patients with metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Camilla Qvortrup

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Eriksen JG

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

3661-3678

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17530020%20AND%20SRC:MED&resulttype=core&format=json

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

The integration of targeted agents into systemic therapy of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Molecular and pathologic aspects of endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Systemic therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

A systematic overview of chemotherapy effects in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Management of advanced colorectal cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

The price tag on progress--chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Monoclonal antibodies in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Trichomegaly of the eyelashes following treatment with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Neoadjuvant therapy with bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

1 reference

7 January 2021

Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

EGFR enhances early healing after cutaneous incisional wounding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Role of panitumumab in the management of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Cetuximab therapy and symptomatic hypomagnesemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Second-line therapy for advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021

Severe acneiform rash

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210377

7 January 2021